147 related articles for article (PubMed ID: 37902460)
1. What's new in the use of antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) DNA cross-linkers for cancer therapy?
Hartley JA
Expert Opin Biol Ther; 2023; 23(11):1049-1052. PubMed ID: 37902460
[No Abstract] [Full Text] [Related]
2. Antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) dimers for cancer therapy.
Hartley JA
Expert Opin Biol Ther; 2021 Jul; 21(7):931-943. PubMed ID: 32543981
[TBL] [Abstract][Full Text] [Related]
3. The Role of Specific ATP-Binding Cassette Transporters in the Acquired Resistance to Pyrrolobenzodiazepine Dimer-Containing Antibody-Drug Conjugates.
Corbett S; Huang S; Zammarchi F; Howard PW; van Berkel PH; Hartley JA
Mol Cancer Ther; 2020 Sep; 19(9):1856-1865. PubMed ID: 32669316
[TBL] [Abstract][Full Text] [Related]
4. Pyrrolobenzodiazepine Dimer Antibody-Drug Conjugates: Synthesis and Evaluation of Noncleavable Drug-Linkers.
Gregson SJ; Masterson LA; Wei B; Pillow TH; Spencer SD; Kang GD; Yu SF; Raab H; Lau J; Li G; Lewis Phillips GD; Gunzner-Toste J; Safina BS; Ohri R; Darwish M; Kozak KR; Dela Cruz-Chuh J; Polson A; Flygare JA; Howard PW
J Med Chem; 2017 Dec; 60(23):9490-9507. PubMed ID: 29112410
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody-Drug Conjugate Targeting 5T4.
Harper J; Lloyd C; Dimasi N; Toader D; Marwood R; Lewis L; Bannister D; Jovanovic J; Fleming R; D'Hooge F; Mao S; Marrero AM; Korade M; Strout P; Xu L; Chen C; Wetzel L; Breen S; van Vlerken-Ysla L; Jalla S; Rebelatto M; Zhong H; Hurt EM; Hinrichs MJ; Huang K; Howard PW; Tice DA; Hollingsworth RE; Herbst R; Kamal A
Mol Cancer Ther; 2017 Aug; 16(8):1576-1587. PubMed ID: 28522587
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Pyrrolobenzodiazepine Dimer Bis-imine versus Mono-imine: DNA Interstrand Cross-linking, Cytotoxicity, Antibody-Drug Conjugate Efficacy and Toxicity.
Tiberghien AC; Vijayakrishnan B; Esfandiari A; Ahmed M; Pardo R; Bingham J; Adams L; Santos K; Kang GD; Pugh KM; Afif-Rider S; Vashisht K; Haque K; Tammali R; Rosfjord E; Savoca A; Hartley JA; Howard PW
Mol Cancer Ther; 2023 Feb; 22(2):254-263. PubMed ID: 36722141
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel polyamide-pyrrolobenzodiazepine hybrids for antibody-drug conjugates.
Thomas JD; Yurkovetskiy AV; Yin M; Bodyak ND; Gumerov DR; Tang S; Kelleher E; Jones BD; Protopopova M; Qin L; Uttard A; Demady DR; Lowinger TB
Bioorg Med Chem Lett; 2022 Sep; 72():128876. PubMed ID: 35788036
[TBL] [Abstract][Full Text] [Related]
8. A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma.
Kahl BS; Hamadani M; Radford J; Carlo-Stella C; Caimi P; Reid E; Feingold JM; Ardeshna KM; Solh M; Heffner LT; Ungar D; He S; Boni J; Havenith K; O'Connor OA
Clin Cancer Res; 2019 Dec; 25(23):6986-6994. PubMed ID: 31685491
[TBL] [Abstract][Full Text] [Related]
9. TR1801-ADC: a highly potent cMet antibody-drug conjugate with high activity in patient-derived xenograft models of solid tumors.
Gymnopoulos M; Betancourt O; Blot V; Fujita R; Galvan D; Lieuw V; Nguyen S; Snedden J; Stewart C; Villicana J; Wojciak J; Wong E; Pardo R; Patel N; D'Hooge F; Vijayakrishnan B; Barry C; Hartley JA; Howard PW; Newman R; Coronella J
Mol Oncol; 2020 Jan; 14(1):54-68. PubMed ID: 31736230
[TBL] [Abstract][Full Text] [Related]
10. CD25-targeted antibody-drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity.
Zammarchi F; Havenith K; Bertelli F; Vijayakrishnan B; Chivers S; van Berkel PH
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32912922
[TBL] [Abstract][Full Text] [Related]
11. Loncastuximab tesirine for treatment of relapsed or refractory diffuse large B cell lymphoma.
Goparaju K; Caimi PF
Expert Opin Biol Ther; 2021 Nov; 21(11):1373-1381. PubMed ID: 34505550
[TBL] [Abstract][Full Text] [Related]
12. Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine.
Hartley JA; Flynn MJ; Bingham JP; Corbett S; Reinert H; Tiberghien A; Masterson LA; Antonow D; Adams L; Chowdhury S; Williams DG; Mao S; Harper J; Havenith CEG; Zammarchi F; Chivers S; van Berkel PH; Howard PW
Sci Rep; 2018 Jul; 8(1):10479. PubMed ID: 29992976
[TBL] [Abstract][Full Text] [Related]
13. Modulating Therapeutic Activity and Toxicity of Pyrrolobenzodiazepine Antibody-Drug Conjugates with Self-Immolative Disulfide Linkers.
Pillow TH; Schutten M; Yu SF; Ohri R; Sadowsky J; Poon KA; Solis W; Zhong F; Del Rosario G; Go MAT; Lau J; Yee S; He J; Liu L; Ng C; Xu K; Leipold DD; Kamath AV; Zhang D; Masterson L; Gregson SJ; Howard PW; Fang F; Chen J; Gunzner-Toste J; Kozak KK; Spencer S; Polakis P; Polson AG; Flygare JA; Junutula JR
Mol Cancer Ther; 2017 May; 16(5):871-878. PubMed ID: 28223423
[TBL] [Abstract][Full Text] [Related]
14. CD25-targeted antibody-drug conjugate camidanlumab tesirine for relapsed or refractory classical Hodgkin lymphoma.
Xu B; Li S; Kang B; Fan S; He Z; Zhou J
Invest New Drugs; 2022 Dec; 40(6):1333-1341. PubMed ID: 36074313
[TBL] [Abstract][Full Text] [Related]
15. Antibody drug conjugates, targeting cancer-expressed EGFR, exhibit potent and specific antitumor activity.
Ho ECH; Qiu R; Miller E; Bilotta MT; FitzGerald D; Antignani A
Biomed Pharmacother; 2023 Jan; 157():114047. PubMed ID: 36459711
[TBL] [Abstract][Full Text] [Related]
16. Efficacy, Tolerability, and Pharmacokinetic Studies of Antibody-Drug Conjugates Containing a Low-Potency Pyrrolobenzodiazepine Dimer.
Gregson SJ; Pugh K; Patel N; Afif-Rider S; Vijayakrishnan B; Santos K; Riedl J; Hutchinson I; Kang GD; Chooi KP; Beard R; Adams L; Barry CS; Ball K; Masterson LA; McFarlane M; Hartley JA; Howard PW
Mol Cancer Ther; 2022 Sep; 21(9):1439-1448. PubMed ID: 35793464
[TBL] [Abstract][Full Text] [Related]
17. Targeting CD19-positive lymphomas with the antibody-drug conjugate loncastuximab tesirine: preclinical evidence as single agent and in combination therapy.
Tarantelli C; Wald D; Munz N; Spriano F; Bruscaggin A; Cannas E; Cascione L; Gaudio E; Arribas AJ; Manjappa S; Golino G; Scalise L; Cacciapuoti MT; Zucca E; Stathis A; Inghirami G; Van Berkel PH; Rossi D; Caimi PF; Zammarchi F; Bertoni F
Haematologica; 2024 May; ():. PubMed ID: 38721745
[TBL] [Abstract][Full Text] [Related]
18. Systematic Variation of Pyrrolobenzodiazepine (PBD)-Dimer Payload Physicochemical Properties Impacts Efficacy and Tolerability of the Corresponding Antibody-Drug Conjugates.
Staben LR; Chen J; Cruz-Chuh JD; Del Rosario G; Go MA; Guo J; Khojasteh SC; Kozak KR; Li G; Ng C; Lewis Phillips GD; Pillow TH; Rowntree RK; Wai J; Wei B; Xu K; Xu Z; Yu SF; Zhang D; Dragovich PS
J Med Chem; 2020 Sep; 63(17):9603-9622. PubMed ID: 32787101
[TBL] [Abstract][Full Text] [Related]
19. Design and characterization of homogenous antibody-drug conjugates with a drug-to-antibody ratio of one prepared using an engineered antibody and a dual-maleimide pyrrolobenzodiazepine dimer.
White JB; Fleming R; Masterson L; Ruddle BT; Zhong H; Fazenbaker C; Strout P; Rosenthal K; Reed M; Muniz-Medina V; Howard P; Dixit R; Wu H; Hinrichs MJ; Gao C; Dimasi N
MAbs; 2019 Apr; 11(3):500-515. PubMed ID: 30835621
[TBL] [Abstract][Full Text] [Related]
20. Improved Therapeutic Window in
Zhong H; Chen C; Tammali R; Breen S; Zhang J; Fazenbaker C; Kennedy M; Conway J; Higgs BW; Holoweckyj N; Raja R; Harper J; Pierce AJ; Herbst R; Tice DA
Mol Cancer Ther; 2019 Jan; 18(1):89-99. PubMed ID: 30352801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
